Cargando…
Repairing the Brain: Gene Therapy
In vivo gene therapy for neurodegenerative disorders has turned out to be a formidable challenge. It is a field not much older than twenty years, but we were many who would have predicted a much easier path towards the clinic using this treatment modality. For Parkinson’s disease patients, this has...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311375/ https://www.ncbi.nlm.nih.gov/pubmed/30584164 http://dx.doi.org/10.3233/JPD-181485 |
_version_ | 1783383605413675008 |
---|---|
author | Björklund, Tomas |
author_facet | Björklund, Tomas |
author_sort | Björklund, Tomas |
collection | PubMed |
description | In vivo gene therapy for neurodegenerative disorders has turned out to be a formidable challenge. It is a field not much older than twenty years, but we were many who would have predicted a much easier path towards the clinic using this treatment modality. For Parkinson’s disease patients, this has meant a frustrating wait, seeing many promising therapies being forgotten after a few pre-clinical proof-of-concept studies. The reasons for this are both scientific and economical. However, this is slowly but surely changing and over the next two decades we will see a very exciting development in this field. In a foreseeable future, gene therapy will be a very natural component of many clinical therapies, not least in Parkinson’s disease. |
format | Online Article Text |
id | pubmed-6311375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63113752019-01-02 Repairing the Brain: Gene Therapy Björklund, Tomas J Parkinsons Dis Review In vivo gene therapy for neurodegenerative disorders has turned out to be a formidable challenge. It is a field not much older than twenty years, but we were many who would have predicted a much easier path towards the clinic using this treatment modality. For Parkinson’s disease patients, this has meant a frustrating wait, seeing many promising therapies being forgotten after a few pre-clinical proof-of-concept studies. The reasons for this are both scientific and economical. However, this is slowly but surely changing and over the next two decades we will see a very exciting development in this field. In a foreseeable future, gene therapy will be a very natural component of many clinical therapies, not least in Parkinson’s disease. IOS Press 2018-12-18 /pmc/articles/PMC6311375/ /pubmed/30584164 http://dx.doi.org/10.3233/JPD-181485 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Björklund, Tomas Repairing the Brain: Gene Therapy |
title | Repairing the Brain: Gene Therapy |
title_full | Repairing the Brain: Gene Therapy |
title_fullStr | Repairing the Brain: Gene Therapy |
title_full_unstemmed | Repairing the Brain: Gene Therapy |
title_short | Repairing the Brain: Gene Therapy |
title_sort | repairing the brain: gene therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311375/ https://www.ncbi.nlm.nih.gov/pubmed/30584164 http://dx.doi.org/10.3233/JPD-181485 |
work_keys_str_mv | AT bjorklundtomas repairingthebraingenetherapy |